Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: A randomized study

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Espinel, Eugenia ^a   Joven, Jorge ^b   Gil, Iván ^a   Suñé, Pilar ^a   Renedo, Berta ^a   Fort, Joan ^a   Serón, Daniel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERKALEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERKALEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 84880874748     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-306     Document Type: Article

References (46)

1. Hyperkalemia in hospitalized patients. Stevens MS, Dunlay RW, Int Urol Nephrol 2000 32 177 180 10.1023/A:1007135517950 11229629 (Pubitemid 32140484)
2. Hyperkalaemia in diabetes: prevalence and associations. Jarman PR, Kehely AM, Mather HM, Postgrad Med J 1995 71 551 552 10.1136/pgmj.71.839.551 7479468
3. Drug-induced hyperkalemia. Ponce SP, Jennings AE, Madias NE, Harrington JT, Med (Baltimore) 1985 64 357 370 (Pubitemid 16197701)
4. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME, BMJ 2000 321 1440 1444 10.1136/bmj.321.7274.1440 11110735
5. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the studies of left ventricular dysfunction (SOLVD) trials. De Denus S, Tardif JC, White M, Bourassa MG, Racine N, Levesque S, Ducharme A, Am Heart J 2006 152 705 712 10.1016/j.ahj.2006.05.030 16996842 (Pubitemid 44396894)
6. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Korgaonkar S, Tilea A, Gillespie BW, Kiser M, Eisele G, Finkelstein F, Kotanko P, Pitt B, Saran R, Clin J Am Nephrol 2010 5 762 769 10.2215/CJN.05850809
7. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D, Kidney Int 2000 58 2084 2092 10.1111/j.1523-1755. 2000.00381.x 11044229
8. Analysis of factors causing hyperkalemia. Takaichi K, Takemoto F, Ubara Y, Mori Y, Intern Med 2007 46 823 829 10.2169/internalmedicine.46.6415 17575373 (Pubitemid 47261663)
9. Electrolyte disorders and arrhythmogenesis. El-Sherif N, Turitto G, Cardiol J 2011 18 233 245 21660912
10. Disorders of potassium balance. Mount DB, Kambiz ZN, et al. Brenner & Rector's the kidney. Volume 1 Philadelphia, USA: Elsevier Saunders, Taal MV, Chertow GM, Marsden PA, 9 2012 640 678 23919660
11. Managing hyperkalemia caused by inhibitors of the renin-angiotensin- aldosterone system. Palmer BF, N Engl J Med 2004 351 585 592 10.1056/NEJMra035279 15295051 (Pubitemid 39025174)
12. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Reardon LC, Macpherson DS, Arch Intern Med 1998 158 26 32 10.1001/archinte.158.1.26 9437375 (Pubitemid 28070442)
13. Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European society of hypertension and of the European society of cardiology. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, et al. J Hipertens 2007 25 1105 1187 10.1097/HJH.0b013e3281fc975a (Pubitemid 46924065)
14. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if serum creatinine and/or serum potassium concentration rises. Palmer BF, Nephrol Dial Trans 2003 18 1973 1975 10.1093/ndt/gfg282 (Pubitemid 37220298)
15. ACC/AHA 2005 guidelines update for the diagnosis and management of chronic heart failure in the adult. Hunt SA, J Am Coll Cardiol 2005 46 1 e82 10.1016/j.jacc.2005.08.022 16168273 (Pubitemid 41316530)
16. Effect of angiotensin-converting-enzime inhibitor benazepril on the progression of chronic renal insufficiency. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P, N Engl J Med 1996 334 939 945 10.1056/NEJM199604113341502 8596594 (Pubitemid 26114159)
17. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, N Engl J Med 1993 329 1456 1462 10.1056/NEJM199311113292004 8413456 (Pubitemid 23335891)
18. The effect of irbesartan on development of diabetic nephropathy in patients with type 2 diabetes. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner PJ, N Engl J Med 2001 345 870 878 10.1056/NEJMoa011489 11565519
19. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, N Engl J Med 2001 345 851 860 10.1056/NEJMoa011303 11565517
20. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Brenner BM, Cooper ME, De Z, Keane WF D, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, N Engl J Med 2001 345 861 869 10.1056/NEJMoa011161 11565518
21. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, Ann Intern Med 2003 139 244 252 10.7326/0003-4819-139-4-200308190-00006 12965979
22. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Weir MR, Rolfe M, Clin J Am Soc Nephrol 2010 5 531 548 10.2215/CJN.07821109 20150448
23. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? Weir MR, Am J Hypertens 1999 12 195S 203S 10619572 (Pubitemid 30029272)
24. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Mckelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J, Circulation 1999 100 1056 1064 10.1161/01.CIR.100.10.1056 10477530 (Pubitemid 29416231)
25. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE, J Hypertens suppl 1994 12 suppl 2 37 42
26. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T, Hypertens Res 2002 25 849 855 10.1291/hypres.25.849 12484508 (Pubitemid 36024640)
27. Efficacy and safety of benazapril for advanced chronic renal insufficiency. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW, N Engl J Med 2006 354 131 140 10.1056/NEJMoa053107 16407508 (Pubitemid 43076710)
28. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, Lancet 1997 349 747 752 10.1016/S0140-6736(97)01187-2 9074572 (Pubitemid 27122456)
29. Hipokalaemia and hyperkalaemia. Rastegar A, Soleimani M, Postgrad Med J 2001 77 759 764 10.1136/pmj.77.914.759 11723313 (Pubitemid 33116510)
30. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 461 470 10.7326/0003-4819-130-6-199903160-00002 10075613 (Pubitemid 29135798)
31. Concurrent and predictive validity of a self-reported measure of medication adherence. Morisky DE, Green LW, Levine DM, Med Care 1986 24 67 74 10.1097/00005650-198601000-00007 3945130 (Pubitemid 16125389)
32. The brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Svarstad BL, Chewning BA, Sleath BL, Claesson C, Patient Educ Couns 1999 37 113 124 10.1016/S0738-3991(98)00107-4 14528539 (Pubitemid 29276860)
33. Efficacy of ramipril versus enalapril in patients with mild to moderate essential hypertension. Yasky J, Verho M, Erasmus TP, Luus HG, Angela M, Grandin L, Akbary MA, Rangoonwala B, Br J Clin Pract 1996 50 302 310 8983318 (Pubitemid 126815410)
34. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials. Omboni S, Malacco E, Mallion JM, Volpe M, Drugs Aging 2012 29 981 992 10.1007/s40266-012-0030-3 23179896
35. Improving ascertainment of sudden cardiac death in patients with end stage renal disease. Pun PH, Herzog CA, Middleton JP, Clin J Am Soc Nephrol 2012 7 116 122 10.2215/CJN.02820311 22076878
36. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non diabetic chronic kidney disease. Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C, Cochrane Database Syst Rev 2011 10 D007751 21975774
37. Angiotensin-converting enzyme i/d polymorphism in patients with malignant hypertension. Espinel E, Tovar JL, Borrellas J, Piera L, Jardi R, Frias FR, Armadans L, Bachs AGJ, J Clin Hypertens (Greenwich) 2005 7 11 15 10.1111/j.1524-6175.2005.03879.x
38. Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus. Preston RA, Baltodano NM, Alonso AB, Epstein M, J Clin Pharmacol 2002 42 754 757 10.1177/009127002401102696 12092742 (Pubitemid 34663532)
39. Sanders GD, Coeytaux R, Dolor RJ, Hasselblad V, Patel UD, Powers B, Gray RN, Irvine RJ, Kendrick A, Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and direct renin inhibitors for treating essential hypertension: an update Rockville (MD): Agency for Healthcare Research and Quality (US), AHRQ Comparative Effectiveness Reviews 2011 11-EHC063-EF
40. Effects of olmesartan and enalapril at low or high doses on cardiac, renal and vascular interstitial matrix in spontaneously hypertensive rats. Porteri E, Rodella L, Rizzoni D, Rezzani R, Paiardi S, Sleiman I, De Ciuceis C, Boari GE, Castellano M, Bianchi R, Agabiti-Rosei E, Blood Press 2005 14 184 192 10.1080/08037050510034211 16036499 (Pubitemid 41015718)
41. A randomized, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild to moderate hypertension. Mimran A, Ruilope L, Kerwin L, Nys M, Owens D, Kassler-Taub K, Osbakken M, J Hum Hypertens 1998 12 203 208 10.1038/sj.jhh.1000591 9579771 (Pubitemid 28140291)
42. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Heran BS, Wong MM, Heran IK, Wright JM, Cochrane Database Syst Rev 2008 4 CD003823
43. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J, J Clin Hypertens (Greenwich) 2001 3 283 291 10.1111/j.1524-6175.2001.01136.x
44. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J, J Hypertens 2007 25 1327 1336 10.1097/HJH.0b013e3280825625 17563549 (Pubitemid 46924066)
45. Design aspects of 24 h recall assessments may affect the estimates of protein and potassium intake in dietary surveys. Crispim SP, Geelen A, Siebelink E, Huybrechts I, Lillegaard IT, Margaritis I, Rehurkova I, Slimani N, Ocke MC, de Boer E, van't Veer P, de Vries JH, Public Health Nutr 2012 15 1196 2000 10.1017/S1368980012000511 22348312
46. Follow-up of markedly elevated serum potassium results in the ambulatory setting: implications for patient safety. Moore CR, Lin JJ, O'Connor N, Halm EA, Am J Med Qual 2006 21 115 124 10.1177/1062860605285047 16533903 (Pubitemid 43375592)